U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06850740) titled 'Efficacy of Co-Spinal Ondansetron In Inguinal Herniorrhaphy' on Feb. 22.
Brief Summary: Ondansetron, a selective serotonin 5-HT3 receptor antagonist, is well known for its antiemetic effects. However, its ability to reduce hypotension during spinal anesthesia has recently sparked great interest. In clinical practice, administering ondansetron before spinal anesthesia has produced promising results.
Study Start Date: March 15
Study Type: INTERVENTIONAL
Condition:
Hernia, Inguinal
Intervention:
DRUG: Ondansetron 8mg
Patients will receive 8 mg of ondansetron (ZOFATRONE(R), 8 mg/4 mL, EVA Pharma, Egypt)
DRUG: Normal Saline
Pati...